Leiras Oy

Schering Aktiengesellschaft

Schering Oy

Matti Lehtinen

Harri Jukarainen

Jarkko Ruohonen

Juha Ala-Sorvari

Tommi Markkula

Walter Elger

Michael Paton

Michael Oettel

John Kelshaw Conway

Sigfrid Schwarz

Gudrun Reddersen

Pekka Lankinen

Christine Talling

Jukka Sepp&auml;l&auml;

Holger Zimmermann

John MacAndrew

Juba Ala-Sorvari

Jarkko Rughonen

Pekka Lähteenmäki

Hannu Allonen

Ilkka Rauramo

Richard Gardner

The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.

Use of biogenic estrogen sulfamates for hormone replacement therapy

A membrane or matrix for controlling the permeation rate of a drug, where the membrane or matrix includes a siloxane-based elastomer composition which contains at least one elastomer and optionally a non-crosslinked polymer. The elastomer composition includes poly(alkylene oxide) groups, and the poly(alkylene oxide) groups are present as blocks in a chain of the elastomer or the polymer, or as blocks and alkoxy-terminated grafts of polysiloxane units, the blocks or blocks and grafts being linked to the polysiloxane units by silicon-carbon bonds, with at least three blocks being present in the elastomer or polymer chain. Methods for the preparation of the elastomer composition are also disclosed.

Membrane or matrix for controlling the permeation rate of drugs

A device for the controlled release over a prolonged period of time of a drug having antiprogestinic properties, the device including a core containing the drug, optionally a membrane encasing the core, where at least one of the core and membrane, when present, is made of a siloxane-based elastomer composition including at least one elastomer and optionally a non-crosslinked polymer. The device is characterized in that the elastomer composition includes poly(alkylene oxide) groups and that the poly(alkylene oxide) groups are present in the elastomer or polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks, the grafts or blocks being linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms.

Devices for the delivery of drugs having antiprogestinic properties

Block copolymers and preparation thereof

The invention relates to a delivery device for the controlled release of the therapeutically active agent gestodene, over a prolonged period of time, at a release rate of 0,1-300 &mgr;g/day, said device comprising a core comprising at least said therapeutically active agent, and a membrane encasing said core wherein said membrane is made of an elastomer. According to the invention, the elastomer is a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, and the release rate of said therapeutically active agent of said delivery device is regulated by the amount of said 3,3,3-trifluoropropyl groups.

Drug delivery device, especially for the delivery of gestodene

The invention relates to a delivery device for the controlled release of a therapeutically active agent, especially an androgen, over a prolonged period of time, said device including a core containing the therapeutically active agent, and a membrane encasing the core wherein the membrane is made of an elastomer. According to the invention, the elastomer is a siloxane-based elastomer which includes 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units.

Drug delivery device, especially for the delivery of androgens

The invention relates to a delivery device for the controlled release of a therapeutically active agent, especially a progestin or an estrogen, over a prolonged period of time, said device including a core which contains the therapeutically active agent, and a membrane encasing the core wherein said membrane is made of an elastomer. According to the invention, the elastomer is a siloxane-based elastomer which includes 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units.

Drug delivery device especially for the delivery of progestins and

The invention relates to a siloxane-based elastomer intended for controlling the permeation of drugs, wherein the elastomer includes 3,3,3,-trifluoropropyl groups attached to the Si-atoms of the siloxane units. The invention relates also to a method for the preparation of a siloxane-based elastomer including 3,3,3,-trifluoropropyl substituents, where the elastomer is intended for controlling the permeation of drugs. In the method either i) a 3,3,3,-trifluoropropyl-substituted vinyl-functional polysiloxane component and a silicon hydride-functional crosslinking agent are crosslinked in the presence of a catalyst, or ii) a 3,3,3,-trifluoropropyl-substituted polysiloxane component is crosslinked in the presence of a peroxide catalyst.

Elastomer, its preparation and use

Inserter for the positioning of an intrauterine device

Intravaginal delivery system

Device for intrauterine use

An implant injection device for once-only use includes an elongated implant housing (10), a cannula (11) and a plunger (20) which is longitudinally movable in the implant housing. The surface (21) of the plunger and the inner wall (15) of the implant housing are equipped with interacting projections (22, 12) which permit the plunger to move inwards into the implant housing but which prevent the removal of the plunger from the implant housing.

Implant injection device

Growing community of inventors

Piispanristi, Finland

Matti Lehtinen